The effect of germ-line BRCA mutations on response to chemotherapy and outcome of recurrent ovarian cancer

International Journal of Gynecological Cancer

Volumn 24, Issue 3, 2014, Pages 488-495

  Safra, Tamar ^a,b   Rogowski, Ori ^a   Muggia, Franco M ^b  

^a TEL AVIV UNIVERSITY   (Israel)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

BRCA mutation; Chemosensitivity; Platinum resistance; Platinum sensitivity; Recurrent ovarian cancer

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; DOCETAXEL; DOXORUBICIN; GEMCITABINE; PACLITAXEL; PLATINUM; TAXANES; TOPOTECAN; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RECURRENCE; CANCER STAGING; COMPARATIVE STUDY; DISEASE COURSE; FEMALE; FOLLOW UP; GENETIC DISORDER; GERM LINE; HUMAN; MAJOR CLINICAL STUDY; MEDICAL RECORD; NONHEREDITARY DISEASE; OUTCOME ASSESSMENT; OVARY CARCINOMA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECURRENT DISEASE; RETROSPECTIVE STUDY; TREATMENT RESPONSE; TUMOR SUPPRESSOR GENE; ADULT; AGED; CARCINOMA; EPIDEMIOLOGY; GENETICS; ISRAEL; MIDDLE AGED; MORTALITY; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA; FEMALE; GENES, BRCA1; GENES, BRCA2; HUMANS; ISRAEL; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84900446817     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0000000000000086     Document Type: Article

References (30)

1. Markman M, HoskinsW. Responses to salvage chemotherapy in ovarian cancer: a critical need for precise definitions of the treated population. J Clin Oncol. 1992;10:513-514.
2. Walsh T, Casadei S, Lee MK, et al. Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing. Proc Natl Acad Sci U S A. 2011;108:18032-18037.
3. Zhang S, Royer R, Li S, et al. Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancer. Gynecol Oncol. 2011;121:353-357.
4. Tutt A, Ashworth A. The relationship between the roles of BRCA genes in DNA repair and cancer predisposition. Trends Mol Med. 2002;8:571-576.
5. Venkitaraman AR. Linking the cellular functions of BRCA genes to cancer pathogenesis and treatment. Annu Rev Pathol. 2009;4:461-487.
6. Gallagher DJ, Konner JA, Bell-McGuinn KM, et al. Survival in epithelial ovarian cancer: a multivariate analysis incorporating BRCA mutation status and platinum sensitivity. Ann Oncol. 2011;22:1127-1132.
7. Safra T, Borgato L, Nicoletto MO, et al. BRCA mutation status and determinant of outcome in women with recurrent epithelial ovarian cancer treated with pegylated liposomal doxorubicin. Mol Cancer Ther. 2011;10:2000-2007.
8. Sessa C. Update on PARP1 inhibitors in ovarian cancer. Ann Oncol. 2011;22:viii72-viii76.
9. Tan DS, Rothermundt C, Thomas K, et al. "BRCAness" syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations. J Clin Oncol. 2008;26:5530-5536.
10. Boyd J, Sonoda Y, Federici MG, et al. Clinicopathologic features of BRCA-linked and sporadic ovarian cancer. JAMA. 2000;283:2260-2265.
11. Cass I, Baldwin RL, Varkey T, et al. Improved survival in women with BRCA-associated ovarian carcinoma. Cancer. 2003;97:2187-2195.
12. Rigakos G, Razis E. BRCAness: finding the Achilles heel in ovarian cancer. Oncologist. 2012;17:956-962.
13. Eisenhauer EA, Therasse P, Bogaerts J, et al. New Response Evaluation Criteria in Solid Tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228-247.
14. Rustin GJ. Use of CA-125 to assess response to new agents in ovarian cancer trials. J Clin Oncol. 2003;21:187s-193s.
15. Andreopoulou E, Gaiotti D, Kim E, et al. Pegylated liposomal doxorubicin HCL (PLD; Caelyx/Doxil): experience with long-term maintenance in responding patients with recurrent epithelial ovarian cancer. Ann Oncol. 2007;18:716-721.
16. Nicoletto MO, Bertorelle R, Borgato L, et al. Family history of cancer rather than p53 status predicts efficacy of pegylated liposomal doxorubicin and oxaliplatin in relapsed ovarian cancer. Int J Gynecol Cancer. 2009;19:1022-1028
17. Fornari FA, Randolph JK, Yalowich JC, et al. Interference by doxorubicin with DNA unwinding in MCF-7 breast tumor cells. Mol Pharmacol. 1994;45:649-656.
18. Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005;434:917-921.
19. Husain A, He G, Venkatraman ES, et al. BRCA1 up-regulation is associated with repair-mediated resistance to cis-diamminedichloroplatinum(II). Cancer Res. 1998;58:1120-1123.
20. Quinn JE, James CR, Stewart GE, et al. BRCA1 mRNA expression levels predict for overall survival in ovarian cancer after chemotherapy. Clin Cancer Res. 2007;13:7413-7420.
21. Heinemann V, Schulz L, Issels RD, et al. Gemcitabine: a modulator of intracellular nucleotide and deoxynucleotide metabolism. Semin Oncol. 1995;22:11-18.
22. Heinemann V, Xu YZ, Chubb S, et al. Cellular elimination of 2?,2?-difluorodeoxycytidine 5?-triphosphate: a mechanism of self-potentiation. Cancer Res. 1992;52:533-539.
23. Hertzberg RP, Caranfa MJ, Hecht SM. On the mechanism of topoisomerase I inhibition by camptothecin: evidence for binding to an enzyme-DNA complex. Biochemistry. 1989;28:4629-4638.
24. Hsiang YH, Lihou MG, Liu LF. Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res. 1989;49:5077-5082.
25. Gallagher BM Jr. Microtubule-stabilizing natural products as promising cancer therapeutics. Curr Med Chem. 2007;14:2959-2967.
26. Chabalier C, Lamare C, Racca C, et al. BRCA1 downregulation leads to premature inactivation of spindle checkpoint and confers paclitaxel resistance. Cell Cycle. 2006;5:1001-1007.
27. Lafarge S, Sylvain V, Ferrara M, et al. Inhibition of BRCA1 leads to increased chemoresistance to microtubule-interfering agents, an effect that involves the JNK pathway. Oncogene. 2001;20:6597-6606.
28. Quinn JE, Kennedy RD, Mullan PB, et al. BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis. Cancer Res. 2003;63:6221-6228.
29. Stordal B, Pavlakis N, Davey R. A systematic review of platinum and taxane resistance from bench to clinic: an inverse relationship. Cancer Treat Rev. 2007;33:688-703.
30. Lesnock JL, Darcy KM, Tian C, et al. BRCA1 expression and improved survival in ovarian cancer patients treated with intraperitoneal cisplatin and paclitaxel: a Gynecologic Oncology Group Study. Br J Cancer. 2013;108:1231-1237.